CARDIOGEN-82
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARDIOGEN-82 (CARDIOGEN-82).
CardioGen-82 (rubidium Rb-82 generator) produces rubidium Rb-82, a positron-emitting radiotracer that is taken up by myocardial cells via the sodium-potassium ATPase pump, reflecting myocardial perfusion. Its distribution is proportional to blood flow, allowing PET imaging of myocardial perfusion defects.
| Metabolism | Rubidium Rb-82 decays by positron emission to stable strontium-82; it is not metabolized enzymatically. Physical half-life is 76 seconds. |
| Excretion | Renal; >90% eliminated unchanged in urine within 24 hours. Fecal excretion is negligible. |
| Half-life | Terminal elimination half-life is 60–90 seconds (for the parent radionuclide Rb-82). Clinical context: Short half-life allows rapid repeat imaging; myocardial uptake is proportional to blood flow. |
| Protein binding | Rb-82 is not significantly protein-bound; <5% bound to plasma proteins. |
| Volume of Distribution | Vd approximately 3.0–4.0 L/kg, indicating extensive distribution into total body water and tissues, including myocardium. |
| Bioavailability | Not applicable for oral route; only administered intravenously, thus bioavailability is 100% by IV. |
| Onset of Action | IV: Immediate (first-pass extraction by myocardium within seconds). |
| Duration of Action | IV: duration of pharmacologic effect is approximately 2–3 minutes (due to rapid decay and redistribution). Clinical note: Imaging acquisition should commence immediately post-injection. |
Single intravenous dose of 0.3-0.6 mCi (11.1-22.2 MBq) followed by a 0.9% sodium chloride flush at 1-3 mL/sec.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment as elimination is primarily through radioactive decay, not renal clearance. |
| Liver impairment | No dose adjustment required for hepatic impairment as elimination is primarily through radioactive decay, not hepatic metabolism. |
| Pediatric use | Dosing should be individualized based on body weight and clinical indication; typical dose is 0.3 mCi (11.1 MBq) per 70 kg, adjusted proportionally for weight. |
| Geriatric use | Elderly patients may receive the same dose as adults; no specific age-related adjustment is recommended, but consider overall clinical status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARDIOGEN-82 (CARDIOGEN-82).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Advise temporary cessation of breastfeeding for a period to minimize radiation exposure to infant, typically for 12-24 hours or as per institutional radiation safety guidelines. Pump and discard milk during this interval. |
| Teratogenic Risk | Rubidium Rb 82 generator is a radioactive diagnostic agent. No human data on developmental toxicity exist. Animal reproductive studies have not been conducted. In pregnant women, only use if clearly needed and potential benefit justifies risk to fetus. Administer lowest necessary radiation dose to minimize fetal exposure. No known teratogenicity from diagnostic radiopharmaceuticals at typical doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to rubidium Rb-82 or any component of the generator eluate."]
| Precautions | ["Radiation exposure risk: The use of CardioGen-82 is associated with radiation exposure, which may increase cancer risk; use only when benefits outweigh risks.","Allergic reactions: Potential for hypersensitivity reactions, including anaphylaxis, due to eluate constituents.","Pregnancy: Risk to fetus from radiation; consider alternative imaging if possible.","Lactation: Interrupt breastfeeding for 12-24 hours after administration to minimize infant exposure."] |
| Food/Dietary | Avoid caffeine-containing foods and beverages (coffee, tea, chocolate, cola) for at least 12-24 hours before the test, as caffeine interferes with pharmacologic stress agents (e.g., adenosine, regadenoson) often used with CardioGen-82. Fasting is typically required for at least 4-6 hours prior to the procedure. No other specific food restrictions. |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond standard precautions for radiopharmaceutical administration. Ensure adequate hydration to facilitate urinary excretion. Monitor for hypersensitivity reactions. Fetal radiation exposure should be minimized; confirm pregnancy status before administration. |
| Fertility Effects | No known effects on fertility from diagnostic doses of rubidium Rb 82. Animal studies not available. Theoretical potential for gonadal radiation exposure with multiple or high-dose administrations; however, diagnostic exposures are low and unlikely to impair fertility. |
| Clinical Pearls | CardioGen-82 (rubidium Rb-82 generator) is used for positron emission tomography (PET) myocardial perfusion imaging. It has a very short half-life (75 seconds), requiring rapid imaging protocols. The generator elutes rubidium-82 from strontium-82, and breakthrough of strontium-82 must be monitored. Contraindicated in patients with severe pulmonary hypertension. Use with caution in patients with renal impairment. Stress testing (pharmacologic or exercise) is typically performed concurrently. Adverse effects include arrhythmia, hypertension, and allergic reactions. Do not administer if the generator eluate contains particulates or discoloration. |
| Patient Advice | This medication is a radioactive tracer used for a heart imaging test (PET scan). · You will receive an injection into a vein, and then images of your heart will be taken. · You may be asked to exercise or given medication to stress your heart during the test. · Inform your doctor if you are pregnant, breastfeeding, or have kidney problems. · Drink plenty of water before and after the test to help flush the radioactive material from your body. · Report any chest pain, difficulty breathing, or allergic reaction (hives, itching) during the procedure. · The radiation exposure is low and considered safe for diagnostic purposes. |